References
- 1. . Hepatocellular carcinoma. Lancet 391(10127), 1301–1314 (2018).
- 2. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J. Epidemiol. 21(6), 401–416 (2011).
- 3. . Epidemiology and surveillance for hepatocellular carcinoma: new trends. J. Hepatol. 72(2), 250–261 (2020).
- 4. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908–943 (2012).
- 5. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68(2), 723–750 (2018).
- 6. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol. Biomarkers Prev. 23(1), 144–153 (2014).
- 7. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clin. Chem. 65(12), 1543–1553 (2019).
- 8. . Diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 15(11), 1301–1314 (2009).
- 9. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 34(4), 570–575 (2001).
- 10. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 20(2), 282–296 (2019).
- 11. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J. Hepatol. 57(1), 101–107 (2012).
- 12. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 154(3), 209–217 (2019).
- 13. Diagnostic performance of des-γ-carboxy prothrombin for hepatocellular carcinoma: a meta-analysis. Gastroenterol. Res. Pract. 2014, 529314 (2014).
- 14. . Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. Am. J. Gastroenterol. 91(7), 1380–1383 (1996).
- 15. . Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 18(4), 990–997 (1993).
- 16. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 85(4), 812–818 (1999).
- 17. . Biomarkers for the early diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 21(37), 10573–10583 (2015).
- 18. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy. PLoS ONE 10(5), e0126649 (2015).
- 19. . AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin. Chim. Acta 313(1-2), 15–19 (2001).
- 20. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am. J. Gastroenterol. 102(10), 2196–2205 (2007).
- 21. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137(1), 110–118 (2009).
- 22. Relationship between lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int. 25(4), 848–853 (2005).
- 23. . Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 111(4), 996–1001 (1996).
- 24. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin. Gastroenterol. Hepatol. 14(6), 875–886.e6 (2016).
- 25. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol. Biomarkers Prev. 28(3), 531–538 (2019).
- 26. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin. Gastroenterol. Hepatol. 4(12), 1528–1536 (2006).
- 27. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br. J. Cancer 110(8), 2090–2098 (2014).
- 28. . Liquid biopsy and multiparametric analysis in management of liver malignancies: new concepts of the patient stratification and prognostic approach. EPMA J. 9(3), 271–285 (2018).
- 29. . The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA J. 9(1), 77–102 (2018).
- 30. . Optimal multiparametric set-up modelled for best survival outcomes in palliative treatment of liver malignancies: unsupervised machine learning and 3 PM recommendations. EPMA J. 11(3), 505–515 (2020).